How One EU Notified Body Transitioned From The Directives To The MDR And What The Change Means For Clients

Less than two months after the MDR applied in the EU, GMED’s Tarik Krim explains how his notified body navigated the early phase of the transition from auditing the directives to the regulation, and how the change has impacted its clients and demand for services.

Imagination idea and transition concept as a leaf changing to a butterfly shape as a fantasy travel and amazing inspirational spirit symbol in a 3D illustration style.
Transitioning from the EU directives to the MDR

The run up to the full implementation of the EU Medical Device Regulation was a period of intense activity and change for notified bodies, which, among other things, had to seek designation against the new rules and adjust from testing against the medical device directives to the much stricter requirements of the MDR.

It has been a challenging time, not least because certain aspects of the new regulation, such as standards and the...

More from Europe

With LDT Rule DOA, Could FDA Shift Focus To RUOs?

 

Now that the US FDA has chosen not to appeal a March ruling effectively killing the agency’s efforts to regulate lab-developed tests as medical devices, will the agency adopt a different strategy to flex its regulatory muscle?

A Year After Exiting The Ventilator Market, Medtronic Recalls Thousands Of Newport Devices

 

After two serious injuries and one death linked to some of its ventilators, Medtronic has recalled the devices and asked customers to stop using them and find alternative means. The action comes more than a year after the company left the market.

‘UK Must Put Adoption On A Par With Innovation’

 
• By 

Market access concerns dominated at the annual BioWales In London event, where AstraZeneca set out industry’s priorities and the UK Office for Life Sciences struck an optimistic tone about how the UK will lastingly improve uptake of innovation.

Sofinnova And NVIDIA Partner To ‘Supercharge’ Computation For European Startups

 

European venture capital firm Sofinnova Partners’ portfolio companies BioCorteX, Bioptimus, Cure51 and Latent Labs will benefit from the investor’s new partnership with tech giant NVIDIA.

More from Geography